fig7
![Imaging after liver-directed therapy: evidenced-based update of the LI-RADS treatment response algorithm](https://image.oaes.cc/a9bc2024-1268-4876-ae63-60f0e0cf80e9/5744.fig.7.jpg)
Figure 7. 56-year-old female with HCV cirrhosis presenting with LR 5 HCC [APHE (A) and washout (B)]. On immediate post-TACE CT, there is dense, homogenous, and complete staining of the targeted HCC (C), LR-TR nonviable. A second patient, 62-year-old male with alcohol and HCV cirrhosis, presents with focal area of staining within his treated tumor on immediate post-TACE imaging (D), LR-TR nonviable. 1 month after TACE, there is decreasing density of the lipiodol within the tumor and new irregular masslike enhancement at the 6-8 o’clock position, LR-TR viable (E). 3 months after lipiodol TACE there is extensive new and increasing irregular masslike enhancement both along the margin and within the treated tumor (F), LR-TR viable.